What is fibrodysplasia ossificans progressiva (FOP)?

FOP is an extremely rare genetic disease characterised by abnormal bone growth in areas of the body where bone is normally not present (called heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. People with FOP may also experience “flare-ups” that are unpredictable episodes of soft tissue swelling, pain, stiffness, and reduced movement. Flare-ups may sometimes lead to additional bone formation.
The OPTIMA Clinical Trial is testing an investigational drug as a potential treatment in people with FOP. The drug being tested is called “investigational” because it hasn’t been approved for use outside of this clinical trial.
In this clinical trial, researchers want to find out if the investigational drug can help reduce signs and symptoms of FOP, such as the number of flare-ups and amount of abnormal bone growth.

Interested in taking part in the OPTIMA Clinical Trial?

en_AUEnglish (Australia)